TXMD
Income statement / Annual
Last year (2024), TherapeuticsMD, Inc.'s total revenue was $1.76 M,
an increase of 35.25% from the previous year.
In 2024, TherapeuticsMD, Inc.'s net income was -$2.18 M.
See TherapeuticsMD, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.76 M |
$1.30 M |
$69.96 M |
$86.95 M |
$64.87 M |
$49.65 M |
$16.10 M |
$16.78 M |
$19.36 M |
$20.14 M |
| Cost of Revenue |
$509,000.00
|
$0.00
|
$1.40 M
|
$18.84 M
|
$15.97 M
|
$6.33 M
|
$2.74 M
|
$2.64 M
|
$4.19 M
|
$4.51 M
|
| Gross Profit |
$1.25 M
|
$1.30 M
|
$68.57 M
|
$68.11 M
|
$48.90 M
|
$43.31 M
|
$13.36 M
|
$14.14 M
|
$15.17 M
|
$15.64 M
|
| Gross Profit Ratio |
0.71
|
1
|
0.98
|
0.78
|
0.75
|
0.87
|
0.83
|
0.84
|
0.78
|
0.78
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$7.09 M
|
$10.43 M
|
$19.79 M
|
$27.30 M
|
$33.85 M
|
$53.94 M
|
$72.04 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$57.90 M
|
$92.60 M
|
$76.95 M
|
$58.82 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$108.20 M
|
$117.05 M
|
$114.23 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.74 M
|
$8.90 M
|
$57.90 M
|
$200.80 M
|
$192.96 M
|
$174.11 M
|
$115.99 M
|
$57.70 M
|
$51.35 M
|
$28.72 M
|
| Other Expenses |
$1.78 M
|
$922,000.00
|
-$117,000.00
|
$272,000.00
|
$1.04 M
|
$612,786.00
|
$2.28 M
|
$695,631.00
|
$367,317.00
|
$95,719.00
|
| Operating Expenses |
$6.52 M
|
$9.83 M
|
$57.90 M
|
$207.88 M
|
$204.44 M
|
$194.52 M
|
$143.58 M
|
$91.77 M
|
$105.42 M
|
$100.83 M
|
| Cost And Expenses |
$6.52 M
|
$9.83 M
|
$59.30 M
|
$226.72 M
|
$220.41 M
|
$200.85 M
|
$146.32 M
|
$94.41 M
|
$109.61 M
|
$105.33 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$26.05 M
|
$16.53 M
|
$0.00
|
$7,699.00
|
$10,824.00
|
$17,442.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$32.92 M
|
$28.58 M
|
$17.38 M
|
$4.68 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$509,000.00
|
$122,000.00
|
$1.19 M
|
$736,000.00
|
$5.47 M
|
$2.45 M
|
$293,886.00
|
$213,117.00
|
$132,451.00
|
$62,400.00
|
| EBITDA |
-$1.83 M |
-$8.40 M |
$11.86 M |
-$78.57 M |
-$149.47 M |
-$156.31 M |
-$127.65 M |
-$76.71 M |
-$89.74 M |
-$85.13 M |
| EBITDA Ratio |
-1.04
|
-6.45
|
0.17
|
-0.9
|
-2.3
|
-3.15
|
-7.93
|
-4.57
|
-4.64
|
-4.23
|
| Operating Income Ratio |
-2.7
|
-6.55
|
0.29
|
-1.61
|
-2.4
|
-3.05
|
-8.09
|
-4.63
|
-4.66
|
-4.23
|
| Total Other Income/Expenses Net |
$2.42 M
|
$781,000.00
|
-$117,000.00
|
$272,000.00
|
-$27.98 M
|
-$24.94 M
|
-$2.40 M
|
$703,330.00
|
$378,141.00
|
$113,161.00
|
| Income Before Tax |
-$2.34 M
|
-$7.74 M
|
$1.07 M
|
-$172.42 M
|
-$183.52 M
|
-$176.15 M
|
-$132.62 M
|
-$76.93 M
|
-$89.88 M
|
-$85.08 M
|
| Income Before Tax Ratio |
-1.33
|
-5.95
|
0.02
|
-1.98
|
-2.83
|
-3.55
|
-8.24
|
-4.58
|
-4.64
|
-4.22
|
| Income Tax Expense |
-$31,000.00
|
-$43,000.00
|
-$91.86 M
|
$33.19 M
|
$29.18 M
|
$19.88 M
|
$2.28 M
|
-$7,699.00
|
$367,317.00
|
-$17,442.00
|
| Net Income |
-$2.18 M
|
-$10.28 M
|
$112.00 M
|
-$205.60 M
|
-$212.70 M
|
-$196.03 M
|
-$132.62 M
|
-$76.93 M
|
-$89.88 M
|
-$85.08 M
|
| Net Income Ratio |
-1.24
|
-7.89
|
1.6
|
-2.36
|
-3.28
|
-3.95
|
-8.24
|
-4.58
|
-4.64
|
-4.22
|
| EPS |
-0.19 |
-0.55 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
| EPS Diluted |
-0.19 |
-0.74 |
-10.35 |
-25.83 |
-38.58 |
-39.79 |
-29.47 |
-18.71 |
-22.92 |
-24.56 |
| Weighted Average Shares Out |
$11.53 M
|
$13.89 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
| Weighted Average Shares Out Diluted |
$11.53 M
|
$10.44 M
|
$9.03 M
|
$7.96 M
|
$5.51 M
|
$4.93 M
|
$4.50 M
|
$4.11 M
|
$3.92 M
|
$3.46 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
